Abstract: An embodiment of a post-biopsy cavity treatment implant includes a first portion including a first porous matrix defining a first controlled pore architecture or crosslinking density, and a second portion coupled to the first portion. The second portion includes a second porous matrix that defines a second controlled pore architecture or a second crosslinking density that is different from the first controlled pore architecture or the first crosslinking density, causing the second portion to swell in a different manner than the first portion when the implant is placed in an aqueous environment.

Abstract: An implant for filling a cavity created by an excisional procedure includes first and second portions. The first portion may include a first collagenous matrix that defines a first selected crosslinking density and the second portion may include a second collagenous matrix that defines a second selected cross-linking density that is different than the first cross-linking density. The first and second cross-linking densities may be selected so as to cause the first and second portions to swell in such a manner that the implant swells into a size and a shape that is similar to the predetermined size and shape of the cavity when the implant is implanted. An aqueous solution may be added to the cavity if the cavity is not sufficiently aqueous to cause the implant to swell.

Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Abstract: A method of treating a cavity created by a percutaneous excisional procedure carried out through an incision includes steps of providing a post-procedure cavity implant, the post-procedure cavity implant including: a radiopaque element; a core portion coupled to the radiopaque element, the core portion including a first porous matrix defining a first controlled pore architecture, and a shell portion coupled to the core portion, the shell portion including a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture; implanting the post-procedure cavity implant into the cavity, and closing the incision.

Abstract: A method of treating a cavity created by a percutaneous excisional procedure carried out through an incision includes steps of providing a post-procedure cavity implant, the post-procedure cavity implant including: a radiopaque element; a core portion coupled to the radiopaque element, the core portion including a first porous matrix defining a first controlled pore architecture, and a shell portion coupled to the core portion, the shell portion including a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture; implanting the post-procedure cavity implant into the cavity, and closing the incision.

Abstract: A method for mapping a lymphatic system following a cavity generating procedure, may include a step of providing a post-biopsy cavity treatment implant, the implant including a collagenous matrix having a non-uniform cross-linking density that is configured to cause the implant to swell non-uniformly when placed within an aqueous environment, the implant including a dye or a pigment contained therein. The provided post-biopsy cavity treatment implant may then be implanted into the cavity and the cavity closed. The dye/pigment may then be caused to be released from the implant and to propagate through the lymphatic system. The propagated dye/pigment may then be visualized in the lymphatic system using a selected visualization mode.

Abstract: An implant for filling a cavity created by an excisional procedure includes first and second portions. The first portion may include a first collagenous matrix that defines a first selected crosslinking density and the second portion may include a second collagenous matrix that defines a second selected cross-linking density that is different than the first cross-linking density. The first and second cross-linking densities may be selected so as to cause the first and second portions to swell in such a manner that the implant swells into a size and a shape that is similar to the predetermined size and shape of the cavity when the implant is implanted. An aqueous solution may be added to the cavity if the cavity is not sufficiently aqueous to cause the implant to swell.

Abstract: A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture.

Abstract: An embodiment of a post-biopsy cavity treatment implant includes a first portion including a first porous matrix defining a first controlled pore architecture or crosslinking density, and a second portion coupled to the first portion. The second portion includes a second porous matrix that defines a second controlled pore architecture or a second crosslinking density that is different from the first controlled pore architecture or the first crosslinking density, causing the second portion to swell in a different manner than the first portion when the implant is placed in an aqueous environment.

Abstract: A method of preparing a pharmaceutically beneficial, pH-sensitive amphipathic drug compound is disclosed. The pH-sensitive amphipathic parent drug compound is converted to a lipophilic derivative which is then combined with a lipophilic carrier for delivery to the lysosomes of target cells. The lipophilic derivative of the parent compound is acted upon by lysosomal enzymes to yield the parent compound. The method is demonstrated for pharmaceutically beneficial porphyrins that may be used as photosensitizers in photodynamic therapy (PDT). In particular, the method is demonstrated for the esterification of chlorin e.sub.6 and pheophorbide a for the photocytotoxic treatment of human bladder tumor cells.

Abstract: Compositions containing by weight chlorophyllin complex in an amount of between about 0.1% and 40.0%, alone or combined with at least one compound from the group consisting of local anesthetics, vasoconstrictors, protectants, counterirritants, astringents, keratolytics, anticholinergics, wound-healing and antimicrobial (antiseptic) agents and one appropriate base (vehicle) from the group consisting of suppositories, ointments, foams, sprays and medicated pads bases for external and intrarectal applications are used to treat anorectal diseases including hemmorrhoids.